369 related articles for article (PubMed ID: 33799768)
1. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.
Rad S M AH; Halpin JC; Mollaei M; Smith Bell SWJ; Hirankarn N; McLellan AD
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799768
[TBL] [Abstract][Full Text] [Related]
2. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy.
Jenkins Y; Zabkiewicz J; Ottmann O; Jones N
Antibodies (Basel); 2021 Apr; 10(2):. PubMed ID: 33925949
[TBL] [Abstract][Full Text] [Related]
3. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
5. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
6. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes.
Nanjireddy PM; Olejniczak SH; Buxbaum NP
Front Immunol; 2023; 14():1121565. PubMed ID: 36999013
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-mediated metabolic reprogramming of chimeric antigen receptor T cells.
Rad SMAH; Halpin JC; Tawinwung S; Suppipat K; Hirankarn N; McLellan AD
Immunol Cell Biol; 2022 Jul; 100(6):424-439. PubMed ID: 35507473
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
9. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
11. A Metabolism Toolbox for CAR T Therapy.
Xu X; Gnanaprakasam JNR; Sherman J; Wang R
Front Oncol; 2019; 9():322. PubMed ID: 31114756
[TBL] [Abstract][Full Text] [Related]
12. The emerging role for CAR T cells in solid tumor oncology.
Klobuch S; Seijkens TTP; Haanen JBAG
Chin Clin Oncol; 2023 Apr; 12(2):19. PubMed ID: 37160670
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria as Playmakers of CAR T-cell Fate and Longevity.
Rostamian H; Khakpoor-Koosheh M; Fallah-Mehrjardi K; Mirzaei HR; Brown CE
Cancer Immunol Res; 2021 Aug; 9(8):856-861. PubMed ID: 34344697
[TBL] [Abstract][Full Text] [Related]
14. Counteracting CAR T cell dysfunction.
Poorebrahim M; Melief J; Pico de Coaña Y; L Wickström S; Cid-Arregui A; Kiessling R
Oncogene; 2021 Jan; 40(2):421-435. PubMed ID: 33168929
[TBL] [Abstract][Full Text] [Related]
15. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
16. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
17. Versatile CAR T-cells for cancer immunotherapy.
Chu F; Cao J; Neelalpu SS
Contemp Oncol (Pozn); 2018 Mar; 22(1A):73-80. PubMed ID: 29628798
[TBL] [Abstract][Full Text] [Related]
18. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
Front Immunol; 2022; 13():954235. PubMed ID: 36091028
[TBL] [Abstract][Full Text] [Related]
19. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer.
Cao B; Liu M; Wang L; Zhu K; Cai M; Chen X; Feng Y; Yang S; Fu S; Zhi C; Ye X; Zhang J; Zhang Z; Yang X; Zhao M; Wu Q; Xu L; Yang L; Lian H; Zhao Q; Zhang Z
Nat Commun; 2022 Oct; 13(1):6203. PubMed ID: 36261437
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
